White paper

A Build vs. Buy Look at Study Activation

How Activate, a SaaS-based Platform, Manages the Complexities of Study Activation

A Build vs. Buy Look at Study Activation

With the advent of technology for clinical trials, an old argument plays out each time a new one is introduced. Should stakeholders build their own solution internally or buy an off-the-shelf tool designed for a specific purpose? In determining whether to build or buy, stakeholders might consider making the decision based on several key factors:

  • Complexities of SSU
  • Knowledge of requirements
  • Cost

For better study activation, each of these factors poses a tough challenge, but combined, they are daunting.

If there is a commitment to improving study activation, it behooves stakeholders to evaluate the pros and cons of building a tool internally versus selecting a purpose-built cloud-based tool, such as Activate, which is proven to shorten cycle-time. Because of the level of complication inherent in building internally, and the need for a detailed understanding of technological requirements, moving toward a no-risk buy option makes the most sense. With this choice, users have ready access to a complete solution and only pay for what they use. This methodology is the last piece of the clinical stack, linking data across the continuum, a much needed functionality for stakeholders seeking to disrupt the long-standing challenges of study activation and replace it with a SaaS-based solution built to speed clinical trial operations.

Download our white paper "A Build vs. Buy Look at Study Activation" to learn how more about key factors that need to be considered when making this determination.

Fill out the form to get your copy today!